MeiraGTx Holdings plc (MGTX) Operating Margin
- Operating margin · 12 months: Value 46.30%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | 46.30% | Operating income / revenue. Period ending 2026-06-30. $184.03M ÷ $397.50M × 100 ≈ 46.30% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | 184.03M USD | Operating Income (Loss) |
| Revenue | 397.50M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | 153.16M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $184.03M | $397.50M | (m) | $153.16M | (m) | 46.30% |
| 2026-03-31 | $-105.19M | $79.76M | (m) | $128.82M | (m) | -131.89% |
| 2025-12-31 | $-105.97M | $81.39M | (m) | $129.62M | (m) | -130.20% |
| 2025-09-30 | $-163.93M | $27.42M | (m) | $122.79M | (m) | -597.91% |
| 2025-06-30 | $-157.92M | $37.92M | (m) | $116.50M | (m) | -416.49% |
| 2025-03-31 | $-159.04M | (m) | (m) | $117.94M | (m) | (m) |
| 2024-12-31 | $-164.21M | $33.28M | (m) | $119.48M | (m) | -493.44% |
| 2024-09-30 | $-176.48M | (m) | (m) | $129.17M | (m) | (m) |
| 2024-06-30 | $-169.20M | (m) | (m) | $130.78M | (m) | (m) |
| 2024-03-31 | $-152.07M | (m) | (m) | $115.78M | (m) | (m) |
| 2023-12-31 | $-137.06M | (m) | (m) | $103.78M | (m) | (m) |
| 2023-09-30 | $-134.36M | $6.69M | (m) | $91.88M | (m) | -2008.70% |
| 2023-06-30 | $-124.41M | $6.40M | (m) | $80.89M | (m) | -1943.27% |
| 2023-03-31 | $-119.38M | $13.62M | (m) | $84.95M | (m) | -876.45% |
| 2022-12-31 | $-116.36M | $15.92M | (m) | $85.72M | (m) | -730.87% |
| 2022-09-30 | $-83.42M | $42.25M | (m) | $77.58M | (m) | -197.45% |
| 2022-06-30 | $-83.17M | $44.38M | (m) | $82.33M | (m) | -187.39% |
| 2022-03-31 | $-79.89M | $38.74M | (m) | $73.52M | (m) | -206.24% |
| 2021-12-31 | $-73.19M | $37.70M | (m) | $67.13M | (m) | -194.14% |
| 2021-09-30 | $-78.29M | $20.45M | (m) | $58.51M | (m) | -382.89% |
| 2021-06-30 | $-64.17M | $18.59M | (m) | $41.53M | (m) | -345.14% |
| 2021-03-31 | $-68.91M | $15.95M | (m) | $42.54M | (m) | -432.08% |
| 2020-12-31 | $-62.55M | $15.56M | (m) | $33.91M | (m) | -401.94% |
| 2020-09-30 | $-54.78M | $18.72M | (m) | $26.42M | (m) | -292.66% |
| 2020-06-30 | $-57.26M | $17.21M | (m) | $26.41M | (m) | -332.71% |
| 2020-03-31 | $-53.26M | $16.72M | (m) | $19.98M | (m) | -318.59% |
| 2019-12-31 | $-58.27M | $13.29M | (m) | $24.88M | (m) | -438.37% |
| 2019-09-30 | $-72.97M | (m) | (m) | $38.16M | (m) | (m) |
| 2019-06-30 | $-76.80M | (m) | (m) | $41.65M | (m) | (m) |
| 2019-03-31 | $-80.75M | (m) | (m) | $39.67M | (m) | (m) |
| 2018-12-31 | $-78.10M | (m) | (m) | $33.62M | (m) | (m) |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $-31.68M | (m) | (m) | $22.36M | (m) | (m) |
| 2017-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |